Press "Enter" to skip to content

KEYNOTE-189 Updates Show Improved Outcomes for Metastatic Nonsquamous NSCLC – Targeted Oncology

admin 0

KEYNOTE-189 Updates Show Improved Outcomes for Metastatic Nonsquamous NSCLC  Targeted Oncology

The phase III KEYNOTE-189 trial led to the FDA approval of the combination of pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with …

“lung cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *